Second, since the usage of second-line injectables demonstrates a decreasing trend compared to bedaquiline and linezolid, to better assist therapeutic regimen development, the WHO has implemented a new definition of XDR-TB as resistance to RIF, bedaquiline or linezolid, and any kind of FQ from 2021 [ 58 ].
← all excerpts
Risk factors associated with morbidity and unfavorable treatment outcome in drug-resistant pulmonary tuberculosis: a case-control study.
1
—
—